Dr. Katz studies amyotrophic lateral sclerosis (ALS), myasthenia gravis, neuromuscular
diseases, pain management, peripheral neuropathy, poliomyelitis, radiculopathies,
and spinal muscular atrophy. He leads clinical trials of pharmacotherapies to slow
the progression of ALS; device trials; a study of the NeuRX Diaphragm Pacing System
to support patients with diaphragm weakness; and observational studies of factors
affecting disease progression. Dr. Katz and others at the Forbes Norris Center
work with researchers at the University of California, San Diego, to study mutations
in RNA binding proteins that cause neuronal dysfunction and death. In 2014, Dr. Katz
and colleagues at CPMC will collaborate with Cedars-Sinai Regenerative Medicine Institute
on new stem cell and gene therapy techniques to treat ALS patients. He is President
of the ALS Research Group—an international ALS research collaboration. He sits
on the medical advisory board for GBS-CIDP Foundation International and the Myasthenia
Gravis Association.
California Pacific Medical Center Research Institute
2324 Sacramento St., Suite 111
San Francisco, CA, 94115
(415) 600-3604
katzjs@cpmcri.org
Primary Research Interests
Related Clinical Trials
A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety, tolerability and effectiveness
of Acthar to slow new muscle weakness in ALS.
Investigator: Jonathan Katz M.D.
Status: Active, Recruiting
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients with Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety and effect of CK-2127107 on respiratory
function (SVC) and muscle function in ALS.
Investigator: Jonathan Katz M.D.
Status: Active, Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)
The purpose of this study is to determine if eculizumab is safe and effective for
the treatment of patients with refractory gMG.
Investigator: Jonathan Katz M.D.
Status: Active, Recruiting
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of ALS
The purpose of this study is to evaluate the safety and efficacy of AMX0035 in subjects
with ALS.
Investigator: Jonathan Katz M.D.
Status: Active, Recruiting
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
The purpose of this study is to identify links that exist between the disease phenotype
and the disease genotype.
Investigator: Jonathan Katz M.D.
Status: Active, Recruiting